Cord Blood America Announces Debt Reduction Tally: $8.7 Million in 2009; $3.7 Million in Third Quarter

LAS VEGAS, Oct. 7 - Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has reduced its debt by a total of $3.7 million in the third quarter of 2009. Total debt eliminated in 2009 is $8.7 million.

"We recently announced the retirements of four separate notes and wanted to give our investors a concise tally for the quarter. We have emphasized to our investors throughout the year that debt reduction is one of the pillars needed for our ongoing and future success. We are pleased that we have been able to consistently announce debt reductions in 2009. We urge our shareholders to continue to follow our progress as we strengthen the Company and its balance sheet for the long term," said Matthew Schissler, co-founder and CEO.

Cord Blood America also announced this year that it retired $2.53 million of long-term debt with an opportunity fund and that it received a $2.3 million commitment to finance its stem cell laboratory and headquarters in Las Vegas.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company’s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com